Characterizing top gated bilayer graphene interaction with its environment by Raman spectroscopy

In this work we study the behavior of the optical phonon modes in bilayer graphene devices by applying top gate voltage, using Raman scattering. We observe the splitting of the Raman G band as we tune the Fermi level of the sample, which is explained in terms of mixing of the Raman (Eg) and infrared (Eu) phonon modes, due to different doping in the two layers. We theoretically analyze our data in terms of the bilayer graphene phonon self-energy which includes non-homogeneous charge carrier doping between the graphene layers. We show that the comparison between the experiment and theoretical model not only gives information about the total charge concentration in the bilayer graphene device, but also allows to separately quantify the amount of unintentional charge coming from the top and the bottom of the system, and therefore to characterize the interaction of bilayer graphene with its surrounding environment

Towards optimal use of antithrombotic therapy of people with cancer at the end of life: a research protocol for the development and implementation of the SERENITY shared decision support tool Thrombosis Research

Background: Even though antithrombotic therapy has probably little or even negative effects on the well-being of people with cancer during their last year of life, deprescribing antithrombotic therapy at the end of life is rare in practice. It is often continued until death, possibly resulting in excess bleeding, an increased disease burden and higher healthcare costs. Methods: The SERENITY consortium comprises researchers and clinicians from eight European countries with specialties in different clinical fields, epidemiology and psychology. SERENITY will use a comprehensive approach combining a realist review, flash mob research, epidemiological studies, and qualitative interviews. The results of these studies will be used in a Delphi process to reach a consensus on the optimal design of the shared decision support tool. Next, the shared decision support tool will be tested in a randomised controlled trial. A targeted implementation and dissemination plan will be developed to enable the use of the SERENITY tool across Europe, as well as its incorporation in clinical guidelines and policies. The entire project is funded by Horizon Europe.Results: SERENITY will develop an information-driven shared decision support tool that will facilitate treatment decisions regarding the appropriate use of antithrombotic therapy in people with cancer at the end of life. Conclusions: We aim to develop an intervention that guides the appropriate use of antithrombotic therapy, prevents bleeding complications, and saves healthcare costs. Hopefully, usage of the tool leads to enhanced empowerment and improved quality of life and treatment satisfaction of people with advanced cancer and their care givers

Human 90 Kda Heat Shock Protein Hsp90 As A Target For Cancer Therapeutics

Protein misfolding causes a phenotype of disorders that is modulated by the action of multi-complexes formed by molecular chaperones and the proteasome machine. Hsp90 is a molecular chaperone involved in maintaining folding, stability and function of many proteins involved in apoptosis, signal-transduction pathways and cell-cycle regulation. Many of these proteins are usually deregulated in cancers and by keeping them active Hsp90 helps the stabilization of tumorogenic cells. Therefore, inhibition of Hsp90 will result in degradation of its client proteins via the proteasome followed by a down regulation of several properties of the malignant phenotype. As a consequence, Hsp90 has been considered to be an appealing target for cancer therapeutics because its inhibition can affect multiple oncogenic pathways simultaneously. Major efforts have generated Hsp90 inhibitors that passed Phase I clinical trials and have entered Phase II trials. Furthermore, other compounds are in development to improve efficacy as antitumor agents. In conclusion, the development of Hsp90 inhibitors is considered to be a good example of medicinal chemistry. Specific important aspects of Hsp90 structure and function, the role of the chaperone in cancer and the development of Hsp90 inhibitors that causes growth arrest and apoptosis in cancer cells are discussed. © 2009 Bentham Science Publishers Ltd.311021Ramos, C.H.I., Ferreira, S.T., Protein folding, misfolding and aggregation: Evolving concepts and conformational diseases (2005) Protein Pept Lett, 12, pp. 213-222Dyson, H.J., Wright, P.E., Intrinsically unstructured proteins and their functions (2005) Nat Rev Mol Cell Biol, 6, pp. 197-208Fandrich, M., Fletcher, M.A., Dobson, C.M., Amyloid fibrils from muscle myoglobin (2001) Nature, 410, pp. 165-166Fandrich, M., Dobson, C.M., The behaviour of polyamino acids reveals an inverse side chain effect in amyloid structure formation (2002) EMBO J, 21, pp. 5682-5690Dobson, C.M., Experimental investigation of protein folding and misfolding (2004) Methods, 34, pp. 4-14Minton, A.P., Implications of macromolecular crowding for protein assembly (2000) Curr Op Struct Biol, 10, pp. 34-39Prusiner, S.B., Shattuck lecture - neurodegenerative diseases and prions (2001) N Engl J Med, 344, pp. 1516-1526Beissinger, M., Buchner, J., How chaperones fold proteins (1998) Biol Chem, 379, pp. 245-259Hartl, F.U., Hayer-Hartl, M., Molecular chaperones in the cytosol, from nascent chain to folded protein (2002) Science, 295, pp. 1852-1858Borges, J.C., Ramos, C.H.I., Protein folding assisted by chaperones (2008) Protein Pept Lett, 12, pp. 256-261Borges, J.C., Peroto, M.C., Ramos, C.H.I., Molecular Chaperone Genes in the SugarCane Expressed Sequence Database (SUCEST) (2001) Gen Mol Biol, 24, pp. 85-92Borges, J.C., Cagliari, T.C., Ramos, C.H.I., Expression and variability of molecular chaperones in the sugarcane expressome (2007) J Plant Physiol, 164, pp. 505-513Cagliari, T.C., Tiroli, A.O., Borges, J.C., Ramos, C.H.I., Identification and in silico expression analysis of eucalyptus expressed sequencing tags (ESTs) encoding molecular chaperones (2005) Gen Mol Biol, 28, pp. 520-528Csermely, P., Chaperone overload is a possible contributor to 'civilization diseases' (2001) Trends Genet, 17, pp. 701-704Chaduri, T.K., Paul, S., Protein-misfolding diseases and chaperone-base therapeutic approaches (2006) FEBS J, 273, pp. 1331-1349Sõti, C., Nagy, E., Giricz, Z., Vígh, L., Csermely, P., Ferdinandy, P., Heat shock proteins as emerging therapeutic targets (2005) Br J Pharmacol, 146, pp. 769-780Macario, A.J.L., de Macario, E.C., Chaperonophaties and chaperonotherapy (2007) FEBS Lett, 581, pp. 3681-3688Powers, M.V., Workman, P., Inhibitors of the heat shock response: Biology and pharmacology (2007) FEBS Lett, 581, pp. 3758-3769Turbyville, T.J., Wijeratne, E.M., Whitesell, L., Gunatilaka, A.A., The anticancer activity of the fungal metabolite terrecyclic acid A is associated with modulation of multiple cellular stress response pathways (2005) Mol Cancer Ther, 4, pp. 1569-1576Westerheide, S.D., Bosman, J.D., Mbadugha, B.N., Celastrols as inducers of the heat shock response and cytoprotection (2004) J Biol Chem, 279, pp. 56053-56060Nagai, N., Nakai, A., Nagata, K., Quercetin suppresses heat shock response by down regulation of HSF1 (1995) Biochem Biophys Res Commun, 208, pp. 1099-1105Dechsupa, S., Kothan, S., Vergote, J., Quercetin, Siamois 1 and Siamois 2 induce apoptosis in human breast cancer MDA-MB-435 cells xenograft in vivo (2007) Cancer Biol Ther, 6, pp. 56-61Prodromou, C., Pearl, L.H., Structure and functional relationships of Hsp90 (2003) Curr Cancer Drug Targets, 3, pp. 301-323Prodomou, C., Roe, S.M., O'brien, R., Ladbury, J.E., Piper, P.W., Pearl, L.H., Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone (1997) Cell, 90, pp. 65-75Stebbins, C.E., Russo, A.A., Schneider, C., Rosen, N., Hartl, F.U., Pavletich, N.P., Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent (1997) Cell, 89, pp. 239-250Marcu, M.G., Chadli, A., Bouhouche, I., Catelli, M., Neckers, L.M., The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone (2000) J Biol Chem, 275, pp. 37181-37186Garnier, C., Lafitte, D., Tsvetkov, P.O., Binding of ATP to heat shock protein 90: Evidence for an ATP-binding site in the C-terminal domain (2002) J Biol Chem, 277, pp. 12208-12214Soti, C., Racz, A., Csermely, P., A nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket (2002) J Biol Chem, 277, pp. 7066-7075Obermann, W.M., Sondermann, H., Russo, A.A., Pavletich, N.P., Hartl, F.U., In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis (1998) J Cell Biol, 143, pp. 901-910Jez, J.M., Chen, J.C., Rastelli, G., Stroud, R.M., Santi, D.V., Crystal Structure and Molecular Modeling of 17-DMAG in Complex with Human Hsp90 (2003) Chem Biol, 10, pp. 361-368Boston, R.S., Viitanen, P.V., Vierling, E., Molecular chaperones and protein folding in plants (1996) Plant Mol Biol, 32, pp. 191-222Sreedhar, A.S., Kalmár, E., Csermely, P., Shen, Y.F., Hsp90 isoforms: Functions, expression and clinical importance (2004) FEBS Lett, 562, pp. 11-15Eustace, B.K., Sakurai, T., Stewart, J.K., Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness (2004) Nat Cell Biol, 6, pp. 507-514Wegele, H., Müller, L., Buchner, J., Hsp70 and Hsp90 - a relay team for protein folding (2004) Rev Physiol Biochem Pharmacol, 151, pp. 1-44Wandinger, S.K., Richter, K., Buchner, J., The Hsp90 chaperone machinery (2008) J Biol Chem, 283, pp. 18473-18477Chiosis, G., Vilenchik, M., Kim, J., Solit, D., Hsp90: The vulnerable chaperone (2004) Drug Discov Today, 9, pp. 881-888Russell, L.C., Whitt, S.R., Chen, M.S., Chinkers, M., Identification of conserved residues required for the binding of a tetratricopeptide repeat domain to heat shock protein 90 (1999) J Biol Chem, 274, pp. 20060-20063Panaretou, B., Siligardi, G., Meyer, P., Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1 (2002) Mol Cell, 10, pp. 1307-1318Kamal, A., Thao, L., Sensintaffar, J., A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors (2003) Nature, 425, pp. 407-410Zhao, R., Davey, M., Hsu, Y.C., Navigating the chaperone network: An integrative map of physical and genetic interactions mediated by the hsp90 chaperone (2005) Cell, 120, pp. 715-727Whitesell, L., Lindquist, S.L., HSP90 and the chaperoning of cancer (2005) Nat Rev Cancer, 5, pp. 761-772Pratt, W.B., The hsp90-based chaperone system: Involvement in signal transduction from a variety of hormone and growth factor receptors (1998) Proc Soc Exp Biol Med, 217, pp. 420-434Nardai, G., Végh, E.M., Prohászka, Z., Csermely, P., Chaperone-related immune dysfunction: An emergent property of distorted chaperone networks.Trends (2006) Immunol, 27, pp. 74-79Citri, A., Harari, D., Shohat, G., Hsp90 recognizes a common surface on client kinases (2006) J Biol Chem, 281, pp. 14361-14369Pearl, L.H., Prodromou, C., Workman, P., The Hsp90 molecular chaperone: An open and shut case for treatment (2008) Biochem J, 410, pp. 439-453Csermely, P., Schnaider, T., Soti, C., Prohaszka, Z., Nardai, G., The 90-kDa molecular chaperone family: Structure, function, and clinical applications. A comprehensive review (1998) Pharmacol Ther, 79, pp. 129-168Buchner J. Hsp90 & Co. a holding for folding. Trends Biochem Sci 199924: 136-41Hanahan, D., Weinberg, R.A., The hallmarks of cancer (2000) Cell, 100, pp. 57-70Workman, P., Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone (2004) Cancer Lett, 206, pp. 149-157Sharp, S., Workman, P., Inhibitors of the HSP90 molecular chaperone: Current status (2006) Adv Cancer Res, 95, pp. 323-348Neckers, L., Heat shock protein 90: The cancer chaperone (2007) J Biosci, 32, pp. 517-530Fortugno, P., Beltrami, E., Plescia, J., Regulation of survivin function by Hsp90 (2003) Proc Natl Acad Sci, 100, pp. 13791-13796Becker, B., Multhoff, G., Farkas, B., Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases (2004) Exp Dermatol, 13, pp. 27-32Eustace, B.K., Jay, D.G., Extracellular roles for the molecular chaperone, hsp90 (2004) Cell Cycle, 3, pp. 1098-1100Sreedhar, A.S., Csermely, P., Heat shock proteins in the regulation of apoptosis: New strategies in tumor therapy: a comprehensive review (2004) Pharmacol Ther, 101, pp. 227-257Munster, P.N., Basso, A., Solit, D., Norton, L., Rosen, N., Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner (2001) Clin Cancer Res, 7, pp. 2228-2236Munster, P.N., Marchion, D.C., Basso, A.D., Rosen, N., Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway (2002) Cancer Res, 62, pp. 3132-3137Basso, A.D., Solit, D.B., Chiosis, G., Giri, B., Tsichlis, P., Rosen, N., Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function (2002) J Biol Chem, 277, pp. 39858-39866Sreedhar, A.S., Mihaly, K., Pato, B., Hsp90 inhibition accelerates cell lysis. Anti-Hsp90 ribozyme reveals a complex mechanism of Hsp90 inhibitors involving both superoxide- and Hsp90-dependent events (2003) J Biol Chem, 278, pp. 35231-35240Sreedhar, A.S., Nardai, G., Csermely, P., Enhancement of complement-induced cell lysis: A novel mechanism for the anticancer effects of Hsp90 inhibitors (2004) Immunol Lett, 92, pp. 157-161Csermely, P., Agoston, V., Pongor, S., The efficiency of multi-target drugs: The network approach might help drug design (2005) Trends Pharmacol Sci, 26, pp. 178-182Neckers, L., Neckers, K., Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update (2005) Expert Opin Emerg Drugs, 10, pp. 137-149Janin, Y.L., Heat shock protein 90 inhibitors. A text book example of medicinal chemistry? (2005) J Med Chem, 48, pp. 7503-7512Solit, D.B., Chiosis, G., Development and application of Hsp90 inhibitors (2008) Drug Discov Today, 13, pp. 38-43Wehrli W. Ansamycins. Chemistry, biosynthesis and biological activity.Top Curr Chem 197772: 21-49Prodromou, C., Roe, S.M., O'Brien, R., Ladbury, J.E., Piper, P.W., Pearl, L.H., Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone (1997) Cell, 90, pp. 65-75Sasaki, K., Yasuda, H., Onodera, K., Growth inhibition of virus transformed cells in vitro and antitumor activity in vivo of geldanamycin and its derivatives (1979) J Antibiot, 32, pp. 849-851Whitesell, L., Mimnaugh, E.G., De Costa, B., Myers, C.E., Neckers, L.M., Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation (1994) Proc Natl Acad Sci, 91, pp. 8324-8328Bagatell, R., Paine-Murrieta, G.D., Taylor, C.W., Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents (2000) Clin Cancer Res, 6, pp. 3312-3318Sittler, A., Lurz, R., Lueder, G., Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease (2001) Hum Mol Genet, 10, pp. 1307-1315Neckers, L., Ivy, S.P., Heat shock protein 90 (2003) Curr Opin Oncol, 15, pp. 419-424Supko, J.G., Hickman, R.L., Grever, M.R., Malspeis, L., Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent (1995) Cancer Chemother Pharmacol, 36, pp. 305-315Egorin, M.J., Zuhowski, E.G., Rosen, D.M., Sentz, D.L., Covey, J.M., Eiseman, J.L., Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1 (2001) Cancer Chemother Pharmacol, 47, pp. 291-302Patel, K., Piagentini, M., Rascher, A., Engineered biosynthesis of geldanamycin analogs for Hsp90 inhibition (2004) Chem Biol, 11, pp. 1625-1633Xie, Q., Gao, C.F., Shinomiya, N., Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion (2005) Oncogene, 24, pp. 3697-3707Schulte, T.W., Neckers, L.M., The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin (1998) Cancer Chemother Pharmacol, 42, pp. 273-279Chiosis, G., Huezo, H., Rosen, N., Mimnaugh, E., Whitesell, L., Neckers, L., 17AAG: Low target binding affinity and potent cell activity - finding an explanation (2003) Mol Cancer Ther, 2, pp. 123-129Workman, P., Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: Unfolding the relationship between pharmacokinetics and pharmacodynamics (2003) Mol Cancer Ther, 2, pp. 131-138Banerji, U., O'donnell, A., Scurr, M., Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies (2005) J Clin Oncol, 23, pp. 4152-4161Sausville, E.A., Tomaszewski, J.E., Ivy, P., Clinical development of 17-allylamino, 17-demethoxygeldanamycin (2003) Curr Cancer Drug Targets, 3, pp. 377-383Modi, S., Stopeck, A.T., Gordon, M.S., Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: A phase I dose-escalation study (2007) J Clin Oncol, 25, pp. 5410-5417Powers, M.V., Workman, P., Inhibitors of the heat shock response: Biology and pharmacology (2007) FEBS Lett, 581, pp. 3758-3769Banerji, U., Affolter, A., Judson, I., Marais, R., Workman, P., BRAF and NRAS mutations in melanoma: Potential relationships to clinical response to HSP90 inhibitors (2008) Mol Cancer Ther, 7, pp. 737-739De Candia, P., Solit, D.B., Giri, D., Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors (2003) Proc Natl Acad Sci, 100, pp. 12337-12342Bisht, K.S., Bradbury, C.M., Mattson, D., Geldanamycin and 17- allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signalling and cytotoxicity (2003) Cancer Res, 63, pp. 8984-8995Smith, V., Sausville, E.A., Camalier, R.F., Fiebig, H.H., Burger, A.M., Comparison of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: Effects on Hsp90 and client proteins in melanoma models (2005) Cancer Chemother Pharmacol, 56 (2), pp. 126-137Egorin, M.J., Lagattuta, T.F., Hamburger, D.R., Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino) -17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats (2002) Cancer Chemother Pharmacol, 49 (1), pp. 7-19Phillips, J.J., Yao, Z.P., Zhang, W., Conformational dynamics of the molecular chaperone Hsp90 in complexes with a co-chaperone and anticancer drugs (2007) J Mol Biol, 372 (5), pp. 1189-1203Delmotte, P., Delmotte-Plaque, J., A new antifungal substance of fungal origin (1953) Nature, 171, p. 344Kwon, H.J., Yoshida, M., Abe, K., Horinouchi, S., Beppu, T., Radicicol, an agent inducing the reversal of transformed phenotypes of src-transformed fibroblasts (1992) Biosci Biotechnol Biochem, 56 (3), pp. 538-539Soga, S., Neckers, L.M., Schulte, T.W., KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules (1999) Cancer Res, 59 (12), pp. 2931-2938Agatsuma, T., Ogawa, H., Akasaka, K., Halohydrin and oxime derivatives of radicicol: Synthesis and antitumor activities (2002) Bioorg Med Chem, 10 (11), pp. 3445-3454Soga, S., Shiotsu, Y., Akinaga, S., Sharma, S.V., Development of radicicol analogues (2003) Curr Cancer Drug Targets, 3 (5), pp. 359-369Marcu, M.G., Schulte, T.W., Neckers, L., Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins (2000) J Natl Cancer Inst, 92 (3), pp. 242-248Yu, X.M., Shen, G., Neckers, L., Hsp90 inhibitors identified from a library of novobiocin analogues (2005) J Am Chem Soc, 127 (37), pp. 12778-12779Llauger, L., He, H., Kim, J., Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90 (2005) J Med Chem, 48 (8), pp. 2892-2905He, H., Zatorska, D., Kim, J., Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90 (2006) J Med Chem, 49 (1), pp. 381-390Sharp, S.Y., Prodromou, C., Boxall, K., Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues (2007) Mol Cancer Ther, 6 (4), pp. 1198-1211Eccles, S.A., Massey, A., Raynaud, F.I., NVP-AUY922: A novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis (2008) Cancer Res, 68 (8), pp. 2850-2860Martin, C.J., Gaisser, S., Challis, I.R., Molecular characterization of macbecin as an hsp90 inhibitor (2008) J Med Chem, 51 (9), pp. 2853-2857Modi, S., Stopeck, A.T., Gordon, M.S., Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: A phase I dose-escalation study (2007) J Clin Oncol, 25 (34), pp. 5410-5417Sydor, J.R., Normant, E., Pien, C.S., Development of 17- allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90 (2006) Proc Natl Acad Sci, 103 (46), pp. 17408-17413Onodera, H., Kaneko, M., Takahashi, Y., Conformational significance of EH21A1-A4, phenolic derivatives of geldanamycin, for Hsp90 inhibitory activity (2008) Bioorg Med Chem Lett, 18 (5), pp. 1577-1580Banerji, U., Sain, N., Sharp, S.Y., An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino- 17-demethoxygeldanamycin and carboplatin in human ovarian cancer models (2008) Cancer Chemother Pharmacol, 62 (5), pp. 769-778Chandarlapaty, S., Sawai, A., Ye, Q., SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers (2008) Clin Cancer Res, 14 (1), pp. 240-248Yu, X., Guo, Z.S., Marcu, M.G., Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228 (2002) J Natl Cancer Inst, 94 (7), pp. 504-513Aoyagi, S., Trevor, K., Archer Modulating molecular chaperone Hsp90 functions through reversible acetylation (2005) Trends in Cell Biology, 15 (11), pp. 565-567Martínez-Ruiz, A., Villanueva, L., González de Orduña, C., S-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities (2005) Proc Natl Acad Sci, 102 (24), pp. 8525-8530Legagneux, V., Morange, M., Bensaude, O., Heat shock increases turnover of 90 kDa heat shock protein phosphate groups in HeLa cells (1991) FEBS Lett, 291 (2), pp. 359-362Zhao, Y.G., Gilmore, R., Leone, G., Coffey, M.C., Weber, B., Lee, P.W., Hsp90 phosphorylation is linked to its chaperoning function. Assembly of the reovirus cell attachment protein (2001) J Biol Chem, 276 (35), pp. 32822-32827Kurokawa, M., Zhao, C., Reya, T., Kornbluth, S., Inhibition of apoptosome formation by suppression of Hsp90beta phosphorylation in tyrosine kinase-induced leukemias (2008) Mol Cell Biol, 28 (17), pp. 5494-5506Beere, H., Death versus survival: Functional interaction between the apoptotic and stress-inducible heat shock protein pathways (2005) J Clin Invest, 115, pp. 2633-2639Gorre, M.E., Ellwood-Yen, K., Chiosis, G., Rosen, N., Sawyers, C.L., BCRABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90 (2002) Blood, 100, pp. 3041-3044Srivastava, P.K., Maki, R.G., Stress-induced proteins in immune response to cancer.Curr Top (1991) Microbiol Immunol, 167, pp. 109-123Ishii, T., Udono, H., Yamano, T., Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96 (1999) J Immunol, 162 (3), pp. 1303-1309Callahan, M.K., Garg, M., Srivastava, P.K., (2008) Heat-shock protein 90 associates with N-terminal extended peptides and is required for direct and indirect antigen presentation.Proc Natl Acad Sci, 105 (5), pp. 1662-1667Brodsky, J.L., C

Mutant P53 Aggregates Into Prion-like Amyloid Oligomers And Fibrils: Implications For Cancer

Over 50% of all human cancers lose p53 function. To evaluate the role of aggregation in cancer, we asked whether wild-type (WT) p53 and the hot-spot mutant R248Q could aggregate as amyloids under physiological conditions and whether the mutant could seed aggregation of the wild-type form. The central domains (p53C) of both constructs aggregated into a mixture of oligomers and fibrils. R248Q had a greater tendency to aggregate than WT p53. Full-length p53 aggregated into amyloid-like species that bound thioflavin T. The amyloid nature of the aggregates was demonstrated using x-ray diffraction, electron microscopy, FTIR, dynamic light scattering, cell viabilility assay, and anti-amyloid immunoassay. The x-ray diffraction pattern of the fibrillar aggregates was consistent with the typical conformation of cross β-sheet amyloid fibers with reflexions of 4.7 Å and 10 Å. A seed of R248Q p53C amyloid oligomers and fibrils accelerated the aggregation of WT p53C, a behavior typical of a prion. The R248Q mutant co-localized with amyloid-like species in a breast cancer sample, which further supported its prion-like effect. A tumor cell line containing mutant p53 also revealed massive aggregation of p53 in the nucleus. We conclude that aggregation of p53 into a mixture of oligomers and fibrils sequestrates the native protein into an inactive conformation that is typical of a prionoid. This prion-like behavior of oncogenic p53 mutants provides an explanation for the negative dominance effect and may serve as a potential target for cancer therapy. © 2012 by The American Society for Biochemistry and Molecular Biology, Inc.287332815228162Vousden, K.H., Lane, D.P., p53 in health and disease (2007) Nat. Rev. Mol. Cell Biol., 8, pp. 275-283Joerger, A.C., Fersht, A.R., Structural biology of the tumor suppressor p53 (2008) Annu. Rev. Biochem., 77, pp. 557-582Ishimaru, D., Andrade, L.R., Teixeira, L.S., Quesado, P.A., Maiolino, L.M., Lopez, P.M., Cordeiro, Y., Silva, J.L., Fibrillar aggregates of the tumor suppressor p53 core domain (2003) Biochemistry, 42, pp. 9022-9027Silva, J.L., Vieira, T.C., Gomes, M.P., Ano Bom, A.P., Lima, L.M., Freitas, M.S., Ishimaru, D., Foguel, D., Ligand binding and hydration in protein misfolding: Insights from studies of prion and p53 tumor suppressor proteins (2010) Acc. Chem. Res., 43, pp. 271-279Galea, C., Bowman, P., Kriwacki, R.W., Disruption of an intermonomer salt bridge in the p53 tetramerization domain results in an increased propensity to form amyloid fibrils (2005) Prot. Sci., 14, pp. 2993-3003Higashimoto, Y., Asanomi, Y., Takakusagi, S., Lewis, M.S., Uosaki, K., Durell, S.R., Anderson, C.W., Sakaguchi, K., Unfolding, aggregation, and amyloid formation by the tetramerization domain from mutant p53 associated with lung cancer (2006) Biochemistry, 45, pp. 1608-1619Rigacci, S., Bucciantini, M., Relini, A., Pesce, A., Gliozzi, A., Berti, A., Stefani, M., The (1-63) region of the p53 transactivation domain aggregates in vitro into cytotoxic amyloid assemblies (2008) Biophys. J., 94, pp. 3635-3646Ishimaru, D., Ano Bom, A.P., Lima, L.M., Quesado, P.A., Oyama, M.F., De Moura Gallo, C.V., Cordeiro, Y., Silva, J.L., Cognate DNA stabilizes the tumor suppressor p53 and prevents misfolding and aggregation (2009) Biochemistry, 48, pp. 6126-6135Levy, C.B., Stumbo, A.C., Ano Bom, A.P., Portari, E.A., Cordeiro, Y., Silva, J.L., De Moura-Gallo, C.V., Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors (2011) Int. J. Biochem. Cell Biol., 43, pp. 60-64Xu, J., Reumers, J., Couceiro, J.R., De Smet, F., Gallardo, R., Rudyak, S., Cornelis, A., Schymkowitz, J., Gain of function of mutant p53 by coaggregation with multiple tumor suppressors (2011) Nat. Chem. Biol., 7, pp. 285-295Chiti, F., Dobson, C.M., Protein misfolding, functional amyloid, and human disease (2006) Annu. Rev. Biochem., 75, pp. 333-366Pastore, A., Temussi, P.A., The two faces of Janus: Functional interactions and protein aggregation (2012) Curr. Opin. Struct. Biol., 22, pp. 30-37Butler, J.S., Loh, S.N., Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain (2003) Biochemistry, 42, pp. 2396-2403Antony, H., Wiegmans, A.P., Wei, M.Q., Chernoff, Y.O., Khanna, K.K., Munn, A.L., Potential roles for prions and protein-only inheritance in cancer (2011) Cancer Metastasis Rev., 31, pp. 1-19Hollstein, M., Sidransky, D., Vogelstein, B., Harris, C.C., p53 mutations in human cancers (1991) Science, 253, pp. 49-53Olivier, M., Hollstein, M., Hainaut, P., TP53 mutations in human cancers: Origins, consequences, and clinical use (2010) Cold Spring Harb. Perspect. Biol., 2, pp. a001008Cordeiro, Y., Kraineva, J., Gomes, M.P., Lopes, M.H., Martins, V.R., Lima, L.M., Foguel, D., Silva, J.L., The amino-terminal PrP domain is crucial to modulate prion misfolding and aggregation (2005) Biophys. J., 89, pp. 2667-2676Cordeiro, Y., Kraineva, J., Ravindra, R., Lima, L.M., Gomes, M.P., Foguel, D., Winter, R., Silva, J.L., Hydration and packing effects on prion folding and β-sheet conversion. High pressure spectroscopy and pressure perturbation calorimetry studies (2004) J. Biol. Chem., 279, pp. 32354-33259Glabe, C.G., Conformation-dependent antibodies target diseases of protein misfolding (2004) Trends Biochem. Sci., 29, pp. 542-547Lai, Z., Colón, W., Kelly, J.W., The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid (1996) Biochemistry, 35, pp. 6470-6482Howie, A.J., Brewer, D.B., Howell, D., Jones, A.P., Physical basis of colors seen in Congo red-stained amyloid in polarized light (2008) Lab. Invest., 88, pp. 232-242Moll, U.M., LaQuaglia, M., Bénard, J., Riou, G., Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors (1995) Proc. Natl. Acad. Sci. U.S.A., 92, pp. 4407-4411Ostermeyer, A.G., Runko, E., Winkfield, B., Ahn, B., Moll, U.M., Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide (1996) Proc. Natl. Acad. Sci. U.S.A., 93, pp. 15190-15194Bom, A.P., Freitas, M.S., Moreira, F.S., Ferraz, D., Sanches, D., Gomes, A.M., Valente, A.P., Silva, J.L., The p53 core domain is a molten globule at low pH: Functional implications of a partially unfolded structure (2010) J. Biol. Chem., 285, pp. 2857-2866Gerweck, L.E., Tumor pH: Implications for treatment and novel drug design (1998) Semin. Radiat. Oncol., 8, pp. 176-182Gomes, M.P., Millen, T.A., Ferreira, P.S.E., Silva, N.L., Vieira, T.C., Almeida, M.S., Silva, J.L., Cordeiro, Y., Prion protein complexed to N2a cellular RNAs through its N-terminal domain forms aggregates and is toxic to murine neuroblastoma cells (2008) J. Biol. Chem., 283, pp. 19616-19625Ishimaru, D., Lima, L.M., Maia, L.F., Lopez, P.M., Ano Bom, A.P., Valente, A.P., Silva, J.L., Reversible aggregation plays a crucial role on the folding landscape of p53 core domain (2004) Biophys. J., 87, pp. 2691-2700Sunde, M., Serpell, L.C., Bartlam, M., Fraser, P.E., Pepys, M.B., Blake, C.C., Common core structure of amyloid fibrils by synchrotron X-ray diffraction (1997) J. Mol. Biol., 273, pp. 729-739Novitskaya, V., Bocharova, O.V., Bronstein, I., Baskakov, I.V., Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons (2006) J. Biol. Chem., 281, pp. 13828-13836Vieira, M.N., Forny-Germano, L., Saraiva, L.M., Sebollela, A., Martinez, A.M., Houzel, J.C., De Felice, F.G., Ferreira, S.T., Soluble oligomers from a non-disease related protein mimic Aβ-induced tau hyperphosphorylation and neurodegeneration (2007) J. Neurochem., 103, pp. 736-748Gomes, M.P., Cordeiro, Y., Silva, J.L., The peculiar interaction between mammalian prion protein and RNA (2008) Prion, 2, pp. 64-66Elledge, R.M., Clark, G.M., Fuqua, S.A., Yu, Y.Y., Allred, D.C., p53 protein accumulation detected by five different antibodies: Relationship to prognosis and heat shock protein 70 in breast cancer (1994) Cancer Res., 54, pp. 3752-3757Moll, U.M., Valea, F., Chumas, J., Role of p53 alteration in primary peritoneal carcinoma (1997) Int. J. Gynecol. Pathol., 16, pp. 156-162Lambert, M.P., Barlow, A.K., Chromy, B.A., Edwards, C., Freed, R., Liosatos, M., Morgan, T.E., Klein, W.L., Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins (1998) Proc. Natl. Acad. Sci. U.S.A., 95, pp. 6448-6453Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, C.W., Glabe, C.G., Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis (2003) Science, 300, pp. 486-489Gottifredi, V., Prives, C., Molecular biology. Getting p53 out of the nucleus (2001) Science, 292, pp. 1851-1852Soussi, T., Béroud, C., Assessing TP53 status in human tumours to evaluate clinical outcome (2001) Nat. Rev. Cancer, 1, pp. 233-240Chowdary, D.R., Dermody, J.J., Jha, K.K., Ozer, H.L., Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway (1994) Mol. Cell Biol., 14, pp. 1997-2003Chen, L., Lu, W., Agrawal, S., Zhou, W., Zhang, R., Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression (1999) Mol. Med., 5, pp. 21-34Goh, A.M., Coffill, C.R., Lane, D.P., The role of mutant p53 in human cancer (2011) J. Pathol., 223, pp. 116-126Joerger, A.C., Rajagopalan, S., Natan, E., Veprintsev, D.B., Robinson, C.V., Fersht, A.R., Structural evolution of p53, p63, and p73: Implication for heterotetramer formation (2009) Proc. Natl. Acad. Sci. U.S.A., 106, pp. 17705-17710Nicholls, C.D., McLure, K.G., Shields, M.A., Lee, P.W., Biogenesis of p53 involves cotranslational dimerization of monomers and post-translational dimerization of dimers. Implications on the dominant negative effect (2002) J. Biol. Chem., 277, pp. 12937-12945Aguzzi, A., Rajendran, L., The transcellular spread of cytosolic amyloids, prions, and prionoids (2009) Neuron, 64, pp. 783-790Frost, B., Diamond, M.I., Prion-like mechanisms in neurodegenerative diseases (2010) Nat. Rev. Neurosci., 11, pp. 155-159Park, S.J., Borin, B.N., Martinez-Yamout, M.A., Dyson, H.J., The client protein p53 adopts a molten globule-like state in the presence of Hsp90 (2011) Nat. Struct. Mol. Biol., 18, pp. 537-541Kocisko, D.A., Vaillant, A., Lee, K.S., Arnold, K.M., Bertholet, N., Race, R.E., Olsen, E.A., Caughey, B., Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides (2006) Antimicrob. Agents Chemother., 50, pp. 1034-1044Caughey, B., Caughey, W.S., Kocisko, D.A., Lee, K.S., Silveira, J.R., Morrey, J.D., Prions and transmissible spongiform encephalopathy (TSE) chemotherapeutics: A common mechanism for anti-TSE compounds? (2006) Acc. Chem. Res., 39, pp. 646-653Vieira, T.C., Reynaldo, D.P., Gomes, M.P., Almeida, M.S., Cordeiro, Y., Silva, J.L., Heparin binding by murine recombinant prion protein leads to transient aggregation and formation of RNA-resistant species (2010) J. Am. Chem. Soc., 133, pp. 334-34

Accidental and experimental salinomycin poisoning in rabbits Intoxicações natural e experimental por salinomicina em coelhos

An outbreak of salinomycin poisoning in rabbits is described. At least 27 out of 2,000 rabbits reared on a farm died after the coccidiostatic drug sulfaquinoxaline was substituted by salinomycin in the feed. An average of 26.9ppm salinomycin was detected in the ration given to the rabbits. Clinical signs included anorexia, apathy and bradykinesia, which progressed to incoordination and recumbency. Gross lesions consisted of pale areas in the skeletal muscles. The histopathological findings showed severe necrotic degenerative myopathy in association with infiltration of neutrophils and macrophages. One rabbit exhibited similar alterations in the myocardium. Mineralization was observed in the affected skeletal muscles in some cases. In order to verify if the poisoning was due to salinomycin, 20 rabbits were divided into five groups and a ration containing the drug at doses of 10, 25, 50, 75 and 100ppm was given. The administration of doses higher than 50ppm resulted in manifestation of the clinical signs seen in the outbreak of poisoning. It was concluded, that probably an error related to the mixture of salinomycin in the feed was the cause of deaths in the spontaneous outbreak of poisoning on the rabbit farm.<br>Relata-se, pela primeira vez, um surto de intoxicação por salinomicina em coelhos. De 2000 animais, no mínimo 27 morreram após troca do coccidiostático sulfaquinoxalina pela salinomicina. A análise de parte da ração detectou 26,9ppm de salinomicina. Os sinais clínicos observados foram anorexia, apatia e lentidão com evolução para incoordenação dos movimentos e decúbito. As lesões macroscópicas consistiram de áreas pálidas na musculatura esquelética. O exame histopatológico evidenciou miopatia degenerativo-necrótica. Adicionalmente, verificou-se reação inflamatória constituída por neutrófilos e macrófagos. Um coelho apresentou lesões similares no miocárdio. Em alguns casos, mineralização estava presente nos músculos esqueléticos afetados. Vinte coelhos experimentais foram divididos em 5 grupos que receberam 10, 25, 50, 75 e 100ppm de salinomicina por via oral, com a finalidade de reproduzir a intoxicação. Os animais que receberam a partir de 50ppm de salinomicina apresentaram sinais clínicos semelhantes aos observados no surto espontâneo. Nossos resultados indicam que, provavelmente, erro na mistura da substância à ração causou a morte dos coelhos

Ionizing radiation effects on food vitamins: a review

Ionizing radiation has been widely used in industrial processes, especially in the sterilization of medicals, pharmaceuticals, cosmetic products, and in food processing. Similar to other techniques of food processing, irradiation can induce certain alterations that can modify both the chemical composition and the nutritional value of foods. These changes depend on the food composition, the irradiation dose and factors such as temperature and presence or absence of oxygen in the irradiating environment. The sensitivity of vitamins to radiation is unpredictable and food vitamin losses during the irradiation are often substantial. The aim of this study was to discuss retention or loss of vitamins in several food products submitted to an irradiation process.<br>Assim como outras técnicas de processamento de alimentos, a irradiação induz certas alterações, que podem modificar a composição química e o valor nutritivo dos alimentos. A natureza e extensão destas mudanças dependem essencialmente da composição do alimento, da dose de irradiação e de fatores tais como a temperatura e a presença ou ausência do oxigênio do ar. Enquanto que algumas vitaminas, como a riboflavina, niacina e vitamina D são bastante estáveis, outras, como a tiamina e vitaminas A e E, são relativamente lábeis. O objetivo da presente revisão foi discutir as prováveis perdas de vitaminas de diversos produtos submetidos ao processo de irradiação